Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.42 |
| ▸ | AKR1B10 | O60218 | 4/20 | 0.40 |
| ▸ | AKR1B1 | P15121 | 4/20 | 0.40 |
| ▸ | CA12 | O43570 | 3/20 | 0.40 |
| ▸ | CA4 | P22748 | 3/20 | 0.40 |
| ▸ | CA6 | P23280 | 3/20 | 0.40 |
| ▸ | CA5A | P35218 | 3/20 | 0.40 |
| ▸ | CA7 | P43166 | 3/20 | 0.40 |
| ▸ | CA9 | Q16790 | 3/20 | 0.40 |
| ▸ | CA14 | Q9ULX7 | 3/20 | 0.40 |
| ▸ | CA5B | Q9Y2D0 | 3/20 | 0.40 |
| ▸ | CA1 | P00915 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | PKM | P14618 | 1/20 | 0.39 |
| ▸ | HTR1A | P08908 | 1/20 | 0.39 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2991861 | 1.00 | MAPT (0.47) | MAPTMEN1KMT2AALOX5AKR1B10 | |
| SCHEMBL13242591 | 0.92 | MAPT (0.51) | MAPTMEN1KMT2AAKR1B10AKR1B1 | |
| SCHEMBL2990320 | 0.89 | TTR (0.54) | MAPTMEN1KMT2AALOX5AKR1B10 | |
| SCHEMBL2990322 | 0.89 | TTR (0.54) | MAPTMEN1KMT2AALOX5AKR1B10 | |
| SCHEMBL4322780 | 0.86 | KMT2A (0.49) | MAPTMEN1KMT2AAKR1B10AKR1B1 | |
| SCHEMBL4330721 | 0.86 | KMT2A (0.49) | MAPTMEN1KMT2AAKR1B10AKR1B1 | |
| SCHEMBL2995317 | 0.84 | CA12 (0.58) | MAPTMEN1KMT2AALOX5AKR1B1 | |
| SCHEMBL1318274 | 0.84 | CA12 (0.58) | MAPTMEN1KMT2AALOX5AKR1B1 | |
| SCHEMBL2990355 | 0.84 | TTR (0.53) | MAPTMEN1KMT2ACA12CA4 | |
| SCHEMBL2990351 | 0.84 | TTR (0.53) | MAPTMEN1KMT2ACA12CA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100179192-A1 | USE OF NITRIC OXIDE RELEASING COMPOUNDS IN THE TREATMENT OF CHRONIC PAIN | NICOX S.A. (FR) | 2010-07-15 | — | — | US | claimed |
| EP-2167070-A1 | USE OF NITRIC OXIDE RELEASING COMPOUNDS IN THE TREATMENT OF CHRONIC PAIN | Nicox S.A. (FR) | 2010-03-31 | — | — | EP | claimed |
| WO-2009007230-A1 | USE OF NITRIC OXIDE RELEASING COMPOUNDS IN THE TREATMENT OF CHRONIC PAIN | NICOX S.A. (FR) | 2009-01-15 | — | — | WO | claimed |
| US-20100179192-A1 | USE OF NITRIC OXIDE RELEASING COMPOUNDS IN THE TREATMENT OF CHRONIC PAIN | NICOX S.A. (FR) | 2010-07-15 | — | — | US | disclosed |
| EP-2167070-A1 | USE OF NITRIC OXIDE RELEASING COMPOUNDS IN THE TREATMENT OF CHRONIC PAIN | Nicox S.A. (FR) | 2010-03-31 | — | — | EP | disclosed |
| WO-2009007230-A1 | USE OF NITRIC OXIDE RELEASING COMPOUNDS IN THE TREATMENT OF CHRONIC PAIN | NICOX S.A. (FR) | 2009-01-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100179192-A1 | USE OF NITRIC OXIDE RELEASING COMPOUNDS IN THE TREATMENT OF CHRONIC PAIN | NOS1, NOS2, NOS3 | MAPT 3861/4885MEN1 4543/4885KMT2A 4349/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.